Literature DB >> 29282219

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage.

Juan Li1,2, Daniel Prins1,2, Hyun Jung Park1,2, Jacob Grinfeld1,2,3, Carlos Gonzalez-Arias1,2,3, Stephen Loughran1,2, Oliver M Dovey4, Thorsten Klampfl1,2, Cavan Bennett2,5, Tina L Hamilton1,2, Dean C Pask1,2, Rachel Sneade1,2, Matthew Williams1,2, Juliet Aungier1,2, Cedric Ghevaert2,5, George S Vassiliou3,4, David G Kent1,2, Anthony R Green1,2,3.   

Abstract

Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF). Multiple different mutations have been reported, but all result in a +1-bp frameshift and generate a novel protein C terminus. In this study, we generated a conditional mouse knockin model of the most common CALR mutation, a 52-bp deletion. The mutant novel human C-terminal sequence is integrated into the otherwise intact mouse CALR gene and results in mutant CALR expression under the control of the endogenous mouse locus. CALRdel/+ mice develop a transplantable ET-like disease with marked thrombocytosis, which is associated with increased and morphologically abnormal megakaryocytes and increased numbers of phenotypically defined hematopoietic stem cells (HSCs). Homozygous CALRdel/del mice developed extreme thrombocytosis accompanied by features of MF, including leukocytosis, reduced hematocrit, splenomegaly, and increased bone marrow reticulin. CALRdel/+ HSCs were more proliferative in vitro, but neither CALRdel/+ nor CALRdel/del displayed a competitive transplantation advantage in primary or secondary recipient mice. These results demonstrate the consequences of heterozygous and homozygous CALR mutations and provide a powerful model for dissecting the pathogenesis of CALR-mutant ET and PMF.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29282219     DOI: 10.1182/blood-2017-09-806356

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

Review 1.  JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.

Authors:  Michele Ciboddo; Ann Mullally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Mutant calreticulin in myeloproliferative neoplasms.

Authors:  Joan How; Gabriela S Hobbs; Ann Mullally
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

3.  Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.

Authors:  Katte Rao Toppaldoddi; Maira da Costa Cacemiro; Olivier Bluteau; Barbara Panneau-Schmaltz; Amélie Pioch; Delphine Muller; Jean-Luc Villeval; Hana Raslova; Stefan N Constantinescu; Isabelle Plo; William Vainchenker; Caroline Marty
Journal:  Oncogene       Date:  2018-10-19       Impact factor: 9.867

4.  Targeting the CALR interactome in myeloproliferative neoplasms.

Authors:  Elodie Pronier; Paolo Cifani; Tiffany R Merlinsky; Katharine Barr Berman; Amritha Varshini Hanasoge Somasundara; Raajit K Rampal; John LaCava; Karen E Wei; Friederike Pastore; Jesper Lv Maag; Jane Park; Richard Koche; Alex Kentsis; Ross L Levine
Journal:  JCI Insight       Date:  2018-11-15

5.  Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice.

Authors:  Veronika Lysenko; Nicole Wildner-Verhey van Wijk; Kathrin Zimmermann; Marie-Christine Weller; Marco Bühler; Mattheus H E Wildschut; Patrick Schürch; Christine Fritz; Ulrich Wagner; Laura Calabresi; Bethan Psaila; Richard A Flavell; Alessandro M Vannucchi; Adam J Mead; Peter J Wild; Stefan Dirnhofer; Markus G Manz; Alexandre P A Theocharides
Journal:  Blood Adv       Date:  2020-06-09

Review 6.  Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.

Authors:  Ruochen Jia; Robert Kralovics
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

Review 7.  Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.

Authors:  Ross L Levine; Elodie Pronier; Tiffany R Merlinsky
Journal:  Clin Cancer Res       Date:  2019-01-17       Impact factor: 12.531

8.  Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms.

Authors:  William Vainchenker; Isabelle Plo; Mira El-Khoury; Xénia Cabagnols; Matthieu Mosca; Gaëlle Vertenoeil; Christophe Marzac; Fabrizia Favale; Olivier Bluteau; Florence Lorre; Amandine Tisserand; Graciela Rabadan Moraes; Valérie Ugo; Jean-Christophe Ianotto; Jerôme Rey; Eric Solary; Lydia Roy; Philippe Rameau; Najet Debili; Florence Pasquier; Nicole Casadevall; Caroline Marty; Stefan N Constantinescu; Hana Raslova
Journal:  Oncogene       Date:  2020-06-22       Impact factor: 9.867

9.  Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Authors:  Manjola Balliu; Laura Calabresi; Niccolò Bartalucci; Simone Romagnoli; Laura Maggi; Rossella Manfredini; Matteo Lulli; Paola Guglielmelli; Alessandro Maria Vannucchi
Journal:  Blood Adv       Date:  2021-04-27

10.  Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I.

Authors:  Najla Arshad; Peter Cresswell
Journal:  J Biol Chem       Date:  2018-05-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.